MAPT and Alzheimer disease: • Used the ATN framework to define participants by biomarker status • 57.1% of participant were A-T-N- • 32.5% of participants were on the AD continuum • 10.4% of participant were suspected non-Alzheimer's pathology • Age and cerebrovascular burden increased with biomarker positivity • Cognitive dysfunction appeared with phosphorylated tau positivity (T+)